Introduction: Giant cells tumor (GCT) of the bone is usually seen in young adults between the ages of 20 and 40. When occurring in older patients, diagnosis and therapeutic specific feature are to be considered. We underline those aspects through this case report.
Case Presentation: We report the case of a 73-year-old man presenting with a painful swelling knee. The diagnosis of GCT of proximal tibia was retained and the patient underwent extensive curettage, subchondral bone grafting and cementation of the residual cavity. The long-term results show a good functional outcome and no recurrence.
Discussion: In this age group, other lesions have similar clinical and radiological presentations as GCT of bone. The diagnosis of a metastatic carcinoma is to be carefully ruled-out in this situation. While the option of large resection with joint arthroplasty is better accepted in ageing patients as a treatment of GCT of bone, this case suggests that jointpreserving methods should also be considered especially when there are no signs of osteoarthritis. While polymethylmethacrylate cementation is an efficient adjuvant in order to reduce recurrences, it may cause secondary osteoarthritis. Subchondral grafting seems to be a good alternative to prevent this complication.
Conclusion: Malignancies should be ruled-out before retaining the diagnosis of GCT of the bone after the age of 50. Conservative surgical treatment is always an option in this age group.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11513688 | PMC |
http://dx.doi.org/10.1016/j.ijscr.2024.110467 | DOI Listing |
Rev Bras Ortop (Sao Paulo)
December 2024
Shaheed Mohtarma Benazir Bhutto Medical College, Karachi, Paquistão.
Surgical procedures of curettage and surgical resection are used to treat giant cell tumor (GCT) of the distal radius, but it is still controversial whether one provides better functional outcomes than the other. The present study aims to determine and compare both procedures regarding complications, local recurrence, and mobility. A complete search of the applicable literature was done and independently assessed by three authors.
View Article and Find Full Text PDFMalays Orthop J
November 2024
Department of Orthopaedic Surgery, Jawaharlal Nehru Medical College and Hospital, Aligarh, India.
Introduction: Recurrence after Giant Cell Tumour (GCT) treatment depends on the type of treatment used. Poly-Methyl-Meth-Acrylate (PMMA) after extended curettage provides structural support and allows for early identification of recurrence but carries a risk of thermal damage to the surrounding healthy tissue. The aim of this study was to compare long-term functional outcomes and complications in patients with GCT around the knee treated with extended curettage and bone grafting or cementation.
View Article and Find Full Text PDFJ Orthop Case Rep
December 2024
Department of Orthopaedics, All India Institute of Medical Sciences, New Delhi, India.
Introduction: Giant cell tumor (GCT) of the bone, although benign, poses significant challenges due to its locally aggressive nature and high recurrence rates post-surgical intervention. Among skeletal GCTs, those affecting the distal radius present unique difficulties, especially when fungating masses encase vital structures such as blood vessels.
Case Report: We present a case of a 28-year-old male with a recurring GCT of the distal radius, where limb-preserving surgery was successfully performed despite encasement of the radial artery.
Int J Surg Case Rep
November 2024
Orthopedic Surgery Department at Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Introduction: A Giant Cell Tumor (GCT) of the bone is a locally osteolytic tumor made up of mononuclear ovoid stromal cells and multinucleated giant cells. It commonly affects long bones like the distal femur and proximal tibia, but can also develop in the cervical spine during the third and fourth decades of life.
Presentation Of Case: A 20-year-old female presented to the clinic with a complaint of neck pain persisting for one month.
Indian J Surg Oncol
December 2024
Department of Pharmacology, All India Institute of Medical Sciences, Bhubaneswar, India.
Despite early promising results with denosumab treatment in giant cell tumor of bone (GCTB), recent studies have raised concerns about a high local recurrence rate following preoperative denosumab administration and joint preservation surgery. This retrospective study evaluated data from 25 high-risk GCT patients (Campanacci grade II or III with features like soft tissue extension, pathological fracture, minimal periarticular or subarticular bone) treated with five doses of neoadjuvant denosumab injection followed by either curettage and cementing ( = 13) or joint reconstruction with fibular graft/endoprosthesis ( = 12) between 2014 and 2019. With an average follow-up of 40 months, the study found only one patient of local recurrence.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!